Skip to content

Comparison of dopamine agonists and endoscopic surgery for treatment of prolactinomas

Comparison of dopamine agonists and endoscopic surgery for treatment of prolactinomas

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037972
Enrollment
Unknown
Registered
2020-09-08
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary adenoma

Interventions

Group 1:DAs

Sponsors

Department of Neurosurgery, Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients who were already dignosised prolactinomas. 2.The patient has signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients concomitantly taking the psychotropic drugs or other drugs causing elevated PRL ; 2.Patients with parkinson disease and is taking dopaminergic agents; 3.Patients with prolactinoma who received Gamma knife treatment; 4.Patients who use any dopamine receptor agonists other than cabergoline; 5.pregnant or lactating women, or women preparing pregnant; 6.Patients with poor compliance, who cannot implement the program strictly.

Design outcomes

Primary

MeasureTime frame
tumor volume;PRL level; visual acuity and Visual field;

Countries

China

Contacts

Public ContactZhebao Wu

Department of Neurosurgery, Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University

617103822@qq.com+86 13918044660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026